The short answer
Avoid adding kava to desipramine without prescriber review. Kava guidance cautions against sedative combinations, while exact-pair clinical risk remains unmeasured.
What this answer covers
Oral Piper methysticum extract, with product and co-sedative details retained.
- Supplement or preparation
- Piper methysticum
- Medication ingredient
- desipramine
Why the combination needs review
Kava guidance advises against combining it with sedative substances. Desipramine can cause drowsiness and impair alertness, making the actual product and other medicines important.
The metabolism study was reassuring within its limits
The tested kava extract did not significantly inhibit the CYP2D6 probe measure in healthy volunteers. This is not a direct desipramine trial or a test of combined sleepiness.
Do not substitute a spacing rule for review
Bring the kava extract, dose and all other sleep products. No tested interval establishes safe co-use with desipramine.
Watch for impaired alertness
Desipramine can affect alertness and coordination. Avoid driving if affected and contact the prescriber if added sleepiness, confusion or unsteadiness appears after a new product. Severe confusion, fainting or inability to wake needs urgent assessment.
Evidence and practical considerations
Side effects & toxicity
Conditional alertness review is supported; no evidence of a universal kava CYP2D6 inhibition effect or a measured exact-pair reaction.
- Exact scope
- Oral Piper methysticum extract, with product and co-sedative details retained. with Exact oral desipramine hydrochloride tablets. RxNorm IN 3247/PIN 203174 hydrochloride. Mainly norepinephrine reuptake activity does not erase the exact label’s serotonin warning. CYP2D6 inhibition can affect concentrations; not assumed identical to CYP3A substrates.
- Medication form and route
- oral
- Timing or duration
- Source-specific single-dose, repeated-dose and observational exposures distinguished.
What remains uncertain
- A human kava probe study was negative for CYP2D6 effects. This does not rule out non-metabolic impairment or cover all extracts.
Factors that may matter: preparation and plant part; clinical indication; dose; other medicines; baseline alertness.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral desipramine.
Exact label warns about serotonin syndrome with tryptophan and St John’s wort, CYP2D6 inhibition, impaired alertness and cardiovascular/anticholinergic effects.
How this applies: RxNorm IN 3247/PIN 203174 hydrochloride. Mainly norepinephrine reuptake activity does not erase the exact label’s serotonin warning. CYP2D6 inhibition can affect concentrations; not assumed identical to CYP3A substrates.
No universal supplement interval, event rate or preparation equivalence established. Original label distinguishes warnings from measured pair-specific results.
Source 2: official guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering the specified supplement.
Advises against use with sedative substances. Kava may cause dizziness and has been linked to rare severe liver injury, including with different extraction methods.
How this applies: Preparation-specific original evidence; no untested antidepressant or route transfer.
Not a desipramine study. Intrinsic liver risk does not establish added desipramine hepatotoxicity; preparation and co-exposure vary.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Three studies each involving sixteen healthy volunteers.
Goldenseal inhibited the probe measure of CYP2D6 by about half; kava, St John’s wort and the other tested herbs did not.
How this applies: Only the named drug, preparation, route and measured endpoints apply.
Surrogate probe endpoint, no desipramine concentrations or clinical toxicity. One extract cannot define every retail goldenseal product.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current exact available claims adjudicated using original captures and explicit identity and comparator limits. | |
| Research summary published |
Article revision: e68422e60d4e58f6
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.